Premium
Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A
Author(s) -
FRANCHINI M.,
GIRELLI D.,
OLIVIERI O.,
CASTAMAN G.,
LIPPI G.,
POLI G.,
SALVAGNO G. L.,
TAGARIELLO G.,
GIUFFRIDA A.,
DE GIRONCOLI M.,
MORFINI M.,
BERNTORP E.,
GANDINI G.
Publication year - 2006
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2006.01297.x
Subject(s) - medicine , haemophilia a , exon , haemophilia , mutation , titer , gene mutation , gastroenterology , gene , immunology , pediatrics , genetics , antibody , biology
Summary. We report the case of a patient with mild haemophilia A, due to a Tyr2105Cys mutation in exon 22 of the C1 domain, who developed a high‐titre factor VIII inhibitor (maximum titre 1600 BU) with recurrent severe haemorrhages and fatal intracranial bleeding. Based on published data, it appears that although this mutation occurs rarely in patients with mild or moderate haemophilia A, it is frequently associated with the development of high‐titre inhibitors.